Allen Nissenson
CIK 1441889 · Chief Medical Officer · last filed 2026-07-06
Allen Nissenson is a Chief Medical Officer who has filed 32 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for RMTI, was dated Jul 6, 2026. Across all open-market trades the lifetime net is −$2.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.32M
4
32
-$2.78M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RMTI | Director | 23,892 | $6.99 | $167.0K | $0 | 8 | 2026-07-06 |
| ELTX | Director | — | $2.95 | — | $0 | 3 | 2025-05-20 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | Director | 938 | $10.00 | $9.4K | $10.9K | 3 | 2022-06-13 |
| DVA | Chief Medical Officer | 8,990 | $239.46 | $2.15M | -$2.79M | 18 | 2014-02-18 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | RMTI | Grant (A) | +9,633 | $0 | EDGAR |
| 2025-05-21 | RMTI | Grant (A) | +50,000 | $0 | EDGAR |
| 2025-05-20 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2024-11-25 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2024-05-23 | RMTI | Grant (A) | +36,111 | $0 | EDGAR |
| 2023-12-29 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2023-05-25 | RMTI | Grant (A) | +24,715 | $0 | EDGAR |
| 2022-06-13 | Elicio Therapeutics, Inc. (ANGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | RMTI | Grant (A) | +25,000 | $0 | EDGAR |
| 2022-05-23 | Elicio Therapeutics, Inc. (ANGN) Delisted | Buy (P) | +9,383 | $10.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.